(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/238420 A3

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 31/14* (2006.01)
A61K 39/12 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2022/062665

(22) International Filing Date:
10 May 2022 (10.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA 2021 70221	10 May 2021 (10.05.2021)	DK
PA 2021 70364	08 July 2021 (08.07.2021)	DK
PA 2022 70113	18 March 2022 (18.03.2022)	DK
PA 2022 70186	07 April 2022 (07.04.2022)	DK

(71) Applicant: **NYKODE THERAPEUTICS ASA** [NO/NO]; Gaustadalléen 21, 0349 Oslo (NO).

(72) Inventors: **FREDRIKSEN, Agnete Brunsvik**; Øvre Rælingsveg 82B, 2005 Rælingen (NO). **BERSAAS, Audun Trygge Haugen**; Nordalveien 81, 0584 Oslo (NO). **GRANUM, Stine**; Østmarkveien 24, 0687 Oslo (NO). **DILLARD, Pierre**; Ullern allé 24, 0381 Oslo (NO).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:
22 December 2022 (22.12.2022)

(54) Title: CO-EXPRESSION OF CONSTRUCTS AND IMMUNOSTIMULATORY COMPOUNDS

(57) Abstract: The present invention relates to vectors, such as DNA plasmids, comprising multiple nucleic acid sequences engineered to be co-expressed as separate molecules. Such separate molecules include a first polypeptide, wherein the first polypeptide comprises a targeting unit that targets antigen-presenting cells, a multimerization unit, such as dimerization unit, and an antigenic unit comprising one or more antigens or parts thereof, and one or more immunostimulatory compounds.

WO 2022/238420 A3